Status:
TERMINATED
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Lead Sponsor:
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Collaborating Sponsors:
Vaincre la Mucoviscidose
GlaxoSmithKline
Conditions:
Cystic Fibrosis
Pseudomonas Aeruginosa
Eligibility:
All Genders
8+ years
Phase:
PHASE4
Brief Summary
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in...
Detailed Description
Each patient received two successive IV antibiotic courses during a period of pulmonary exacerbation. One of these courses was delivered as thrice daily 30-minute infusions of ceftazidime in 100 ml of...
Eligibility Criteria
Inclusion
- patients with cystic fibrosis older than 8 years
- with chronic Pseudomonas aeruginosa infection of the respiratory tract
- with at least 2 courses of IV antibiotic in the year before enrolment
- at the time of a pulmonary exacerbation
Exclusion
- allergy to ceftazidime or tobramycin
- bronchial colonization with Burkholderia cepacia
- renal impairment
- history of lung transplantation
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00333385
Start Date
October 1 2001
End Date
April 1 2004
Last Update
June 5 2006
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble
Grenoble, France, 38043
2
Centre hospitalier Dr Schaffner
Lens, France, 62307
3
Hopital Albert Calmette
Lille, France, 59000
4
Hopital Jeanne de Flandre
Lille, France, 59000